Q0515 HCPCS Level II code: Injection, sermorelin acetate, 1 microgram
Q0515 is the HCPCS code for “Injection, sermorelin acetate, 1 microgram” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q0515Injection, sermorelin acetate, 1 microgram
Short description: Sermorelin acetate injection
HCPCS · United States
Medicare details
The indicators CMS publishes with Q0515 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2006
Where Q0515 sits
- 1Q codesTemporary codes
- 2Active code Q0515Injection, sermorelin acetate, 1 microgram
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q0515 mean?
Q0515 is the HCPCS code for “Injection, sermorelin acetate, 1 microgram” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q0515?
CMS lists Q0515’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q0515
All Q codesQ0509Miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under medicare part aQ0510Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplantQ0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodQ0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodQ0513Pharmacy dispensing fee for inhalation drug(s); per 30 daysQ0514Pharmacy dispensing fee for inhalation drug(s); per 90 daysQ0516Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 30-daysQ0517Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-daysQ0518Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-daysQ0519Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-daysQ0520Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-daysQ0521Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription